ImClone Investigational Site

Houston, Texas 77030-4009

0 studies enrolling now · 12 studies all time

What they study most

Adenocarcinoma, Breast Cancer, Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Head and Neck Cancer, Metastatic Malignant Melanoma, Myeloid Leukemia, Non-small Cell Lung Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Studies at this site

• Study of IMC-EB10 in Participant With Leukemia — Stopped early
• Study of Ramucirumab in Ovarian Cancer — Completed
• Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma — Completed
• A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma — Completed
• Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck — Completed
• A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer — Completed
• Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma — Completed
• Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) — Completed